Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
Status:
Completed
Trial end date:
2018-10-30
Target enrollment:
Participant gender:
Summary
The goal of this study is to assess whether canagliflozin has a renal and vascular protective
effect in reducing the progression of renal impairment relative to placebo in participants
with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD) and
macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled
daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor
blocker (ARB).